(Press-News.org) A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children's Research Hospital.
The drug, called vismodegib, is designed to block a key protein in the sonic hedgehog (SHH) signaling pathway. The pathway is normally active during fetal development and is inappropriately switched on in about 30 percent of medulloblastoma tumors, including about 60 percent of tumors in adults and 25 percent of tumors in children.
Medulloblastoma develops in the cerebellum at the base of the skull and involves four different subtypes, each with different genetic alterations. The tumor is diagnosed in as many as 400 children and adolescents annually in the U.S., making it the most common malignant pediatric brain tumor. Medulloblastoma is less common in adults, who account for about one-third of newly identified patients each year.
As expected, only patients with the SHH subtype responded to vismodegib; however, researchers also reported that the drug was not universally effective against all tumors in the subtype. The findings were published this month online ahead of print in the Journal of Clinical Oncology.
"While it was disappointing that not all medulloblastoma patients with the SHH subtype will benefit, for the right patients these results mark the beginning of a new era of targeted therapy for treatment of this tumor," said first and corresponding author Giles Robinson, M.D., an assistant member of the St. Jude Department of Oncology. "The findings also highlight the importance of ongoing research to identify the genetic alterations that define who the right patients are and help identify those most likely to benefit from this drug as well as those for whom different therapy is needed."
Vismodegib received federal approval in 2012 for treatment of adults with advanced basal cell carcinoma. Preclinical research by St. Jude scientists helped to set the stage for trials of the drug in medulloblastoma patients. This Pediatric Brain Tumor Consortium study involved Phase II clinical trials that included 31 adults and 12 children with advanced medulloblastoma. Participants all had medulloblastoma that persisted or returned following standard treatment with surgery, radiation and combination chemotherapy.
Tumors shrank or disappeared completely for eight or more weeks in four study participants, including three adults, following vismodegib treatment. In 13 patients, or 41 percent of participants with SHH medulloblastoma, disease stabilized and tumors stopped growing for as long as 17 months during vismodegib therapy.
The findings led to the drug being included in the St. Jude clinical trial for newly diagnosed pediatric medulloblastoma patients aged 3 to 22 years old. Patients with SHH medulloblastoma receive vismodegib as maintenance therapy.
A detailed molecular analysis of patient tumors in this study confirmed scientific suggestions that the location of genetic alterations in the SHH pathway helped to predict vismodegib sensitivity, a proposition that had not been systematically evaluated until now. The drug is engineered to inhibit smoothened, which is a key protein in the SHH pathway. Vismodegib-sensitive tumors were characterized by alterations in genes like PTCH1, which precede the gene that encodes smoothened in the SHH pathway.
Researchers also identified other genetic alterations, particularly in the tumor suppressor gene p53, associated with limited effectiveness of the drug against SHH medulloblastoma.
"This means complete genetic profiling of all sonic hedgehog medulloblastoma is needed to identify the patients who will benefit from vismodegib and those who are candidates for another therapy," Robinson said.
Such profiling will also help researchers develop combination therapies to overcome or avoid vismodegib resistance, he said.
"Tumor response to vismodegib in this study was transient, probably due to the development of drug resistance," Robinson said. "The finding that these tumors also contain other targetable mutations suggests several possible combination therapies that may increase sensitivity to vismodegib and combat drug resistance."
Overall survival for patients with SHH medulloblastoma is 70 percent, but the outlook is dismal for those with recurrent disease. In addition, current treatments often involve significant lifelong side effects that impact the ability of survivors to complete their education and live independently. "The great hope is that targeted therapies will help more patients survive with fewer long-term side effects," Robinson said.
INFORMATION:
The other study authors are Brent Orr, Gang Wu, Tong Lin, Ibrahim Qaddoumi, Sue Kaste, Michael Rusch, Sariah Allen, Arzu Onar-Thomas, Clinton Stewart, James Boyett, David Ellison and Amar Gajjar, all of St. Jude; Richard Gilbertson, previously of St. Jude; Sridharan Gururangan and Annick Desjardins, both of Duke University Medical Center, Durham, N.C.; Roger Packer, Children's National Medical Center, Washington D.C.; Stewart Goldman, Ann and Robert H. Lurie Children's Hospital of Chicago; Michael Prados, University of California, San Francisco; Murali Chintagumpala, Texas Children's Cancer Center, Houston; Naoko Takebe, National Cancer Institute, Bethesda, MD; Maryam Fouladi, Cincinnati Children's Hospital; and Tom Curran, Children's Hospital of Philadelphia.
The research was funded in part by grants (CA81457, CA21765) from the National Institutes of Health; the Noyes Brain Tumor Foundation; Musicians Against Childhood Cancer and ALSAC.
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell. The engineered ribosome may enable the production of new drugs and next-generation biomaterials and lead to a better understanding of how ribosomes function.
The artificial ribosome, called Ribo-T, was created in the laboratories of Alexander Mankin, director of the UIC College of Pharmacy's Center for Biomolecular Sciences, ...
It's one thing to grow bacteria in a test tube, perform a screen in the lab, and find a mutation in the pathogen's genes. It's a whole other thing, and much rarer, to find the exact same mutation in nature--in this case, in E. coli in urine samples from some 500 patients suffering from relapsing urinary tract infections.
The confluent discovery, by University Distinguished Professor Kim Lewis and his colleagues, was published on Wednesday in the journal Nature. It could put people with relapsing UTIs on the fast track for a new therapeutic regimen that Lewis described ...
RICHLAND, Wash. -- Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot -- and where. The model can also suggest the most effective way to reduce soot on the plateau, easing the amount of warming the region undergoes.
The work, which appeared in Atmospheric Chemistry and Physics in June, shows that soot pollution on and above the Himalayan-Tibetan Plateau area warms the region enough to contribute to earlier ...
Following several years of research and collaboration, physicians and engineers at Johns Hopkins and Walter Reed National Military Medical Center say they have developed a computer platform that provides rapid, real-time feedback before and during facial transplant surgery, which may someday improve face-jaw-teeth alignment between donor and recipient.
Surgeons performed the first successful transplant of facial features, including the jaw and teeth, in 2008, mainly relying on visual judgment. Since then, approximately 30 facial transplants have been done worldwide, ...
Brown dwarfs are relatively cool, dim objects that are difficult to detect and hard to classify. They are too massive to be planets, yet possess some planetlike characteristics; they are too small to sustain hydrogen fusion reactions at their cores, a defining characteristic of stars, yet they have starlike attributes.
By observing a brown dwarf 20 light-years away using both radio and optical telescopes, a team led by Gregg Hallinan, assistant professor of astronomy at Caltech, has found another feature that makes these so-called failed stars more like supersized planets--they ...
CHAPEL HILL, NC - The stem cells in our gut divide so fast that they create a completely new population of epithelial cells every week. But this quick division is also why radiation and chemotherapy wreak havoc on the gastrointestinal systems of cancer patients - such therapies target rapidly dividing cells. Scientists at the UNC School of Medicine and the UNC Lineberger Comprehensive Cancer Center found that a rare type of stem cell is immune to radiation damage thanks to high levels of a gene called Sox9.
The discovery, which was made in mice and published in the journal ...
Washington, DC--The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for treating Cushing's syndrome, a condition caused by overexposure to the hormone cortisol.
The CPG, entitled "Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline," was published online and will appear in the August 2015 print issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of the Endocrine Society.
Cushing's syndrome occurs when a person has excess cortisol in the blood for an extended period, according ...
Enrolling in an insurance plan under the Affordable Care Act is only the first step for consumers to be actively engaged in their health care, according to a new analysis from RAND Corporation researchers.
To understand the issues facing consumers as well as the payers, providers and support organizations who work directly with them, RAND researchers conducted phone-based interviews with insurance companies, physician groups and community support nonprofit organizations. The analysis of the interviews shows more work is necessary to support consumers past the point of ...
Kindergarteners' social-emotional skills are a significant predictor of their future education, employment and criminal activity, among other outcomes, according to Penn State researchers.
In a study spanning nearly 20 years, kindergarten teachers were surveyed on their students' social competence. Once the kindergarteners reached their 20s, researchers followed up to see how the students were faring, socially and occupationally. Students demonstrating better prosocial behavior were more likely to have graduated college, to be gainfully employed and to not have been arrested ...
TORONTO, ON - People who have inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, have twice the odds of having a generalized anxiety disorder at some point in their lives when compared to peers without IBD, according to a new study published by University of Toronto researchers.
"Patients with IBD face substantial chronic physical problems associated with the disease," said lead-author Professor Esme Fuller-Thomson, Sandra Rotman Endowed Chair at the University of Toronto's Factor-Inwentash Faculty of Social Work. "The additional burden of ...
